Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients

Urologic Oncology: Seminars and Original Investigations Nov 18, 2017

Biro K, et al. - An inquiry was pursued with regard to the overall survival (OS) of chemotherapy refractory patients with metastatic castration-resistant prostate cancer who were treated with abiraterone acetate + prednisolone (AA + P) beyond prostate-specific antigen (PSA) and radiographic progression (PRP) until clinical progression in comparison to patients treated until PRP. The independent factors of longer OS were discovered to be low levels of AP at the start of treatment, systemic therapy applied after AA + P and treatment beyond PRP, in metastatic castration-resistant prostate cancer.
Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen